Natera
- Market cap
- 57.02B
- P/E (TTM)i
- -293.01
- P/Bi
- 31.30
- EPSi
- -1.52
- Div yieldi
- 0.00%
- 52W posi
- 84%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Natera (NTRA) | 57.02B | -293.01 | 31.30 | 0.00% |
| Thermo Fisher Scientific (TMO) | 244.79B | 35.63 | 4.65 | 0.27% |
| Danaher (DHR) | 153.60B | 38.81 | 2.92 | 0.66% |
| Agilent Technologies (A) | 47.67B | 33.35 | 6.47 | 0.60% |
| Waters (WAT) | 42.84B | 110.38 | 2.82 | 0.00% |
| IQVIA Holdings (IQV) | 42.48B | 32.10 | 6.88 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 20.5% above Morningstar's fair value estimate.
Fair value
Natera Inc earns a 1-star quantitative star rating, reflecting our opinion that this share class poses considerable downside risk. Those looking for diamonds in the rough should steer clear. The stock currently trades at a 31% premium over our quantitative fair value estimate of $314.54 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The company's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 372.4, which falls in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.
The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.2%, a core component of profitability, sits in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.